MUC1 and cholangiocarcinoma: For example, the detection of specific alterations of MUC1 glycosylation allowed patients with cholangiocarcinoma, hepatolithiasis, and normal controls (p < 0.0001) to be distinguished, verifying the cholangiocarcinoma-related glycosylation changes by the lectin-antibody sandwich ELISA.